<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404310</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-Zinc</org_study_id>
    <nct_id>NCT03404310</nct_id>
  </id_info>
  <brief_title>Zinc Sulfate for Human Papillomavirus (HPV)</brief_title>
  <official_title>Oral Zinc Sulfate for the Treatment of High Risk Cervical HPV Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Human Papillomavirus (HPV) is well established as the primary causative agent in both
      warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high
      rate of spontaneous resolution this takes time and the infection can cause cervical cells to
      progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in
      immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high
      risk HPV versus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon enrollment eligible participants will be randomized and given a three-month supply of
      zinc sulfate or placebo to be taken as directed. They will have zinc serum lab testing at
      enrollment and upon study completion. Patients will also be asked to complete short
      questionnaires and to make study staff aware of any side effects they should experience.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blinded placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance rates of high risk HPV</measure>
    <time_frame>During 3 month treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression versus Regression</measure>
    <time_frame>During 3 month treatment period</time_frame>
    <description>Incidence of progression versus regression of cervical changes after treatment with oral zinc sulfate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>After 3 month treatment period</time_frame>
    <description>Rates of side effects from zinc sulfate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance Rates</measure>
    <time_frame>After 3 month treatment period</time_frame>
    <description>Examine rates of patients finishing the 3-month course of zinc sulfate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parity</measure>
    <time_frame>After 3 month treatment period</time_frame>
    <description>Examine the correlation of parity on HPV clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Zinc Levels and Persistence</measure>
    <time_frame>After 3 month treatment period</time_frame>
    <description>Examine potential correlation between low serum levels of zinc and persistence of HPV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zinc Levels and Regression</measure>
    <time_frame>After 3 month treatment period</time_frame>
    <description>Examine the relation between zinc levels before and after treatment and the relation to regression of HPV.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Zinc Sulfate 220mg twice daily for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gelatin Placebo tablet twice daily for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc Sulfate</intervention_name>
    <description>Participant will take one 220mg tablet twice daily for three months.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Gelatin Tablet)</intervention_name>
    <description>Participant will take one tablet twice daily for three months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Abnormal cytology of atypical squamous cells of undetermined significance (ASCUS) on
             Pap smear OR

          -  Low-grade squamous intra epithelial lesions (LSIL) on Pap smear OR

          -  Positive hrHPV on routine screening (positive HPV will be assumed to be high grade)

        Exclusion Criteria:

          -  Patients who proceed to excisional procedures (loop electrosurgical excision procedure
             or cold knife conization)

          -  Pregnant patients

          -  Breastfeeding patients

          -  Immunocompromised patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Prudnick, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole A Walker, BS</last_name>
    <phone>616-486-6332</phone>
    <email>nicole.walker@spectrumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea L Mantel, BS</last_name>
    <phone>616-486-2051</phone>
    <email>andrea.mantel@spectrumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole A Walker, BS</last_name>
      <phone>616-486-6332</phone>
      <email>nicole.walker@spectrumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Andrea L Mantel, BS</last_name>
      <phone>616-486-2051</phone>
      <email>andrea.mantel@spectrumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca Prudnick, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Werkema, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15.</citation>
    <PMID>20952254</PMID>
  </reference>
  <reference>
    <citation>Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999 Nov;180(5):1415-23.</citation>
    <PMID>10515798</PMID>
  </reference>
  <reference>
    <citation>Muñoz N, Méndez F, Posso H, Molano M, van den Brule AJ, Ronderos M, Meijer C, Muñoz A; Instituto Nacional de Cancerologia HPV Study Group. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004 Dec 15;190(12):2077-87. Epub 2004 Nov 22.</citation>
    <PMID>15551205</PMID>
  </reference>
  <reference>
    <citation>Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 1998 Aug;68(2 Suppl):447S-463S. doi: 10.1093/ajcn/68.2.447S. Review.</citation>
    <PMID>9701160</PMID>
  </reference>
  <reference>
    <citation>Al-Gurairi FT, Al-Waiz M, Sharquie KE. Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial. Br J Dermatol. 2002 Mar;146(3):423-31.</citation>
    <PMID>11952542</PMID>
  </reference>
  <reference>
    <citation>Simonart T, de Maertelaer V. Systemic treatments for cutaneous warts: a systematic review. J Dermatolog Treat. 2012 Feb;23(1):72-7. doi: 10.3109/09546634.2010.500324. Epub 2010 Nov 6. Review.</citation>
    <PMID>21054194</PMID>
  </reference>
  <reference>
    <citation>Stefani M, Bottino G, Fontenelle E, Azulay DR. [Efficacy comparison between cimetidine and zinc sulphate in the treatment of multiple and recalcitrant warts]. An Bras Dermatol. 2009 Jan-Feb;84(1):23-9. English, Portuguese.</citation>
    <PMID>19377755</PMID>
  </reference>
  <reference>
    <citation>Kim JH, Bae SN, Lee CW, Song MJ, Lee SJ, Yoon JH, Lee KH, Hur SY, Park TC, Park JS. A pilot study to investigate the treatment of cervical human papillomavirus infection with zinc-citrate compound (CIZAR®). Gynecol Oncol. 2011 Aug;122(2):303-6. doi: 10.1016/j.ygyno.2011.04.026. Epub 2011 May 24.</citation>
    <PMID>21605892</PMID>
  </reference>
  <reference>
    <citation>Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, Snijders PJ, Meijer CJ; POBASCAM Study Group. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer. 2007 May 7;96(9):1419-24. Epub 2007 Mar 6.</citation>
    <PMID>17342094</PMID>
  </reference>
  <reference>
    <citation>Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001 Nov 24;358(9295):1782-3.</citation>
    <PMID>11734239</PMID>
  </reference>
  <reference>
    <citation>López-García DR, Gómez-Flores M, Arce-Mendoza AY, de la Fuente-García A, Ocampo-Candiani J. Oral zinc sulfate for unresponsive cutaneous viral warts: too good to be true? A double-blind, randomized, placebo-controlled trial. Clin Exp Dermatol. 2009 Dec;34(8):e984-5. doi: 10.1111/j.1365-2230.2009.03623.x.</citation>
    <PMID>20055878</PMID>
  </reference>
  <reference>
    <citation>Fosmire GJ. Zinc toxicity. Am J Clin Nutr. 1990 Feb;51(2):225-7. Review.</citation>
    <PMID>2407097</PMID>
  </reference>
  <reference>
    <citation>Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Muñoz N, Franceschi S; HPV Study Group. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003 Sep 1;158(5):486-94.</citation>
    <PMID>12936904</PMID>
  </reference>
  <reference>
    <citation>Raza N, Khan DA. Zinc deficiency in patients with persistent viral warts. J Coll Physicians Surg Pak. 2010 Feb;20(2):83-6. doi: 02.2010/JCPSP.8386.</citation>
    <PMID>20378032</PMID>
  </reference>
  <reference>
    <citation>Miranda PM, Silva NN, Pitol BC, Silva ID, Lima-Filho JL, Carvalho RF, Stocco RC, Beçak W, Lima AA. Persistence or clearance of human papillomavirus infections in women in Ouro Preto, Brazil. Biomed Res Int. 2013;2013:578276. doi: 10.1155/2013/578276. Epub 2013 Nov 5.</citation>
    <PMID>24298551</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>ASCUS</keyword>
  <keyword>LSIL</keyword>
  <keyword>Cervical Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

